{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:46:40Z","timestamp":1793274400368,"version":"4.5.0"},"reference-count":138,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Primary liver cancers include hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), combined hepatocellular\u2013cholangiocarcinoma (cHCC-CCA), and rarer hepatic malignancies. Their biomarker landscapes differ substantially. HCC has many approved systemic therapies, yet most are still selected through clinical context, liver function, tumor burden, and treatment line. By contrast, iCCA and broader biliary tract cancers (BTCs) have fewer patients but multiple treatment-directing genomic alterations, including FGFR2 fusions or rearrangements, IDH1 mutations, HER2 positivity, BRAF V600E, NTRK or RET fusions, and microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) status. cHCC-CCA adds a diagnostic layer because lineage classification and sampling adequacy influence whether HCC-based or BTC-based evidence is more relevant. This review organizes biomarkers by the treatment decision they are expected to support. It covers curative intent and locoregional risk stratification, molecularly guided systemic therapy, immune-state assessment, dynamic monitoring, resistance reassessment, and translational readiness. Across these settings, biomarker value depends on clinical action, evidence maturity, assay feasibility, and timing. The review separates decision-ready markers, trial-enrichment tools, monitoring assays, and mechanistic signatures.<\/jats:p>","DOI":"10.1097\/hc9.0000000000001069","type":"journal-article","created":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:02:52Z","timestamp":1793246572000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Molecular biomarkers for diagnosis, prognosis, precision therapy, and immunotherapy in cholangiocarcinoma, cHCC-CCA, and HCC"],"prefix":"10.1097","volume":"10","author":[{"given":"Jingguo","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Ruan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,11]]},"reference":[{"key":"R1-20261029","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20261029","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","author":"Alvaro","year":"2023","journal-title":"J Hepatol"},{"key":"R3-20261029","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"key":"R4-20261029","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"R5-20261029","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jamasurg.2021.0954","article-title":"Dynamic \u03b1-fetoprotein response and outcomes after liver transplant for hepatocellular carcinoma","volume":"156","author":"Halazun","year":"2021","journal-title":"JAMA Surg"},{"key":"R6-20261029","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"R7-20261029","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"R8-20261029","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41590-024-01992-w","article-title":"Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma","volume":"25","author":"Shu","year":"2024","journal-title":"Nat Immunol"},{"key":"R9-20261029","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"R10-20261029","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","article-title":"Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): A randomised, controlled, phase 2b\/3 trial","volume":"21","author":"Mazzaferro","year":"2020","journal-title":"Lancet Oncol"},{"key":"R11-20261029","doi-asserted-by":"crossref","first-page":"e13634","DOI":"10.1111\/ctr.13634","article-title":"Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality","volume":"33","author":"Mahmud","year":"2019","journal-title":"Clin Transplant"},{"key":"R12-20261029","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/LVT.0000000000000149","article-title":"AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study","volume":"29","author":"Mehta","year":"2023","journal-title":"Liver Transpl"},{"key":"R13-20261029","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.jhep.2023.08.020","article-title":"AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation","volume":"79","author":"Norman","year":"2023","journal-title":"J Hepatol"},{"key":"R14-20261029","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11901-025-00686-7","article-title":"The role of AFP-L3 and DCP biomarkers in the diagnosis and management of hepatocellular carcinoma","volume":"24","author":"Norman","year":"2025","journal-title":"Curr Hepatology Rep"},{"key":"R15-20261029","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.3390\/jcm11175075","article-title":"Diagnostic performance of AFP, AFP-L3, or PIVKA-II for hepatitis C virus-associated hepatocellular carcinoma: A multicenter analysis","volume":"11","author":"Liu","year":"2022","journal-title":"J Clin Med"},{"key":"R16-20261029","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000537897","article-title":"Urgent global need for PIVKA-II and AFP-L3 measurements for surveillance and management of hepatocellular carcinoma","volume":"13","author":"Kudo","year":"2024","journal-title":"Liver Cancer"},{"key":"R17-20261029","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/SLA.0b013e31821ad884","article-title":"Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria","volume":"254","author":"Lim","year":"2011","journal-title":"Ann Surg"},{"key":"R18-20261029","first-page":"e75007","article-title":"Predicting microvascular invasion in liver transplant recipients for hepatocellular carcinoma","volume":"16","author":"Aujla","year":"2024","journal-title":"Cureus"},{"key":"R19-20261029","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jhep.2026.02.019","article-title":"Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL)","volume":"85","author":"Bhoori","year":"2026","journal-title":"J Hepatol"},{"key":"R20-20261029","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/JHC.S289840","article-title":"Association of postoperative biomarker response with recurrence and survival in patients with hepatocellular carcinoma and high alpha-fetoprotein expressions (>400 ng\/ml)","volume":"8","author":"Liang","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"R21-20261029","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1177\/00031348241227202","article-title":"The prognostic value of alpha-fetoprotein ratio in patients with resectable alpha-fetoprotein-negative hepatocellular carcinoma","volume":"90","author":"Sun","year":"2024","journal-title":"Am Surg"},{"key":"R22-20261029","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jhep.2024.06.018","article-title":"Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection","volume":"81","author":"Fuster-Anglada","year":"2024","journal-title":"J Hepatol"},{"key":"R23-20261029","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2024.10.043","article-title":"Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma","volume":"82","author":"Yoo","year":"2025","journal-title":"J Hepatol"},{"key":"R24-20261029","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jhep.2025.07.031","article-title":"Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma","volume":"84","author":"Jeong","year":"2026","journal-title":"J Hepatol"},{"key":"R25-20261029","first-page":"334","article-title":"Evaluation of GALAD score in diagnosis and follow-up of hepatocellular carcinoma after local ablative therapy","volume":"11","author":"Eletreby","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"R26-20261029","doi-asserted-by":"crossref","first-page":"e0466","DOI":"10.1097\/HC9.0000000000000466","article-title":"Development and validation of a biomarker index for HCC treatment response","volume":"8","author":"Liang","year":"2024","journal-title":"Hepatol Commun"},{"key":"R27-20261029","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2147\/JHC.S480540","article-title":"A transcriptomic biomarker for predicting the response to TACE correlates with the tumor microenvironment and radiomics features in hepatocellular carcinoma","volume":"11","author":"Wang","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"key":"R28-20261029","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): A multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"R29-20261029","doi-asserted-by":"crossref","first-page":"538","DOI":"10.21037\/atm.2020.02.124","article-title":"Comparison of albumin-bilirubin grade versus Child-Pugh score in predicting the outcome of transarterial chemoembolization for hepatocellular carcinoma using time-dependent ROC","volume":"8","author":"Zhao","year":"2020","journal-title":"Ann Transl Med"},{"key":"R30-20261029","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2147\/JHC.S319215","article-title":"Biochemical safety of ablative yttrium-90 radioembolization for hepatocellular carcinoma as a function of percent liver treated","volume":"8","author":"De la Garza-Ramos","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"R31-20261029","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijrobp.2021.04.012","article-title":"The potential for midtreatment albumin-bilirubin (ALBI) score to individualize liver stereotactic body radiation therapy","volume":"111","author":"Jackson","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R32-20261029","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jhep.2026.03.019","article-title":"Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French Genomic Medicine Initiative","volume":"85","author":"Campani","year":"2026","journal-title":"J Hepatol"},{"key":"R33-20261029","doi-asserted-by":"crossref","first-page":"104003","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open"},{"key":"R34-20261029","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ccell.2019.04.007","article-title":"Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes","volume":"35","author":"Xue","year":"2019","journal-title":"Cancer Cell"},{"key":"R35-20261029","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov"},{"key":"R36-20261029","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(18)30146-3","article-title":"Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): A final analysis of a phase 3, randomised, placebo-controlled study","volume":"19","author":"Rimassa","year":"2018","journal-title":"Lancet Oncol"},{"key":"R37-20261029","doi-asserted-by":"crossref","first-page":"e2300328","DOI":"10.1200\/PO.23.00328","article-title":"Activity of tepotinib in hepatocellular carcinoma with high-level MET amplification: Preclinical and clinical evidence","volume":"8","author":"Qin","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"R38-20261029","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","article-title":"EGFR activation limits the response of liver cancer to lenvatinib","volume":"595","author":"Jin","year":"2021","journal-title":"Nature"},{"key":"R39-20261029","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41392-024-02085-8","article-title":"Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: A prospective, single-arm exploratory trial","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R40-20261029","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000488541","article-title":"Characterization of hepatocellular carcinoma patients with FGF19 amplification assessed by fluorescence in situ hybridization: A large cohort study","volume":"8","author":"Kang","year":"2019","journal-title":"Liver Cancer"},{"key":"R41-20261029","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1038\/s41598-021-84117-9","article-title":"The impact of FGF19\/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma","volume":"11","author":"Kanzaki","year":"2021","journal-title":"Sci Rep"},{"key":"R42-20261029","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1053\/j.gastro.2023.01.023","article-title":"EGFR\/ERBB2 amplifications and alterations associated with resistance to lenvatinib in hepatocellular carcinoma","volume":"164","author":"Lim","year":"2023","journal-title":"Gastroenterology"},{"key":"R43-20261029","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000547669","article-title":"Vessels that encapsulate tumor cluster+ unresectable hepatocellular carcinomas benefit of antiangiogenic therapy","volume":"15","author":"De Carlo","year":"2025","journal-title":"Liver Cancer"},{"key":"R44-20261029","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1186\/s12967-024-05296-3","article-title":"A multi-parametric prognostic model based on clinicopathologic features: Vessels encapsulating tumor clusters and hepatic plates predict overall survival in hepatocellular carcinoma patients","volume":"22","author":"Xiong","year":"2024","journal-title":"J Transl Med"},{"key":"R45-20261029","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1158\/1078-0432.CCR-23-0459","article-title":"FDA Approval Summary: Selpercatinib for the treatment of advanced RET fusion-positive solid tumors","volume":"29","author":"Duke","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R46-20261029","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jhep.2023.08.017","article-title":"Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab\/bevacizumab","volume":"79","author":"Limousin","year":"2023","journal-title":"J Hepatol"},{"key":"R47-20261029","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"R48-20261029","doi-asserted-by":"crossref","first-page":"103488","DOI":"10.1016\/j.esmoop.2024.103488","article-title":"An open-label study of pemigatinib in cholangiocarcinoma: Final results from FIGHT-202","volume":"9","author":"Vogel","year":"2024","journal-title":"ESMO Open"},{"key":"R49-20261029","doi-asserted-by":"crossref","first-page":"106306","DOI":"10.1016\/j.esmoop.2026.106306","article-title":"Phase III trial of infigratinib versus gemcitabine\/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: Results and reflections on early termination of PROOF 301","volume":"11","author":"Abou-Alfa","year":"2026","journal-title":"ESMO Open"},{"key":"R50-20261029","doi-asserted-by":"crossref","first-page":"113587","DOI":"10.1016\/j.ejca.2024.113587","article-title":"Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies","volume":"200","author":"Parisi","year":"2024","journal-title":"Eur J Cancer"},{"key":"R51-20261029","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"R52-20261029","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1158\/1078-0432.CCR-25-2153","article-title":"HER2 positivity as a prognostic biomarker and therapeutic target in advanced biliary tract cancer: A multi-institutional analysis","volume":"32","author":"Lee","year":"2026","journal-title":"Clin Cancer Res"},{"key":"R53-20261029","doi-asserted-by":"crossref","first-page":"106048","DOI":"10.1016\/j.esmoop.2025.106048","article-title":"Mutational patterns and ancestry-linked profiles in a large hepatocellular carcinoma and combined hepatocellular-cholangiocarcinoma cohort","volume":"11","author":"Gerdes","year":"2026","journal-title":"ESMO Open"},{"key":"R54-20261029","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.23.01193","article-title":"Trastuzumab plus gemcitabine-cisplatin for treatment-na\u00efve human epidermal growth factor receptor 2-positive biliary tract adenocarcinoma: A multicenter, open-label, phase ii study (TAB)","volume":"42","author":"Ostwal","year":"2024","journal-title":"J Clin Oncol"},{"key":"R55-20261029","doi-asserted-by":"crossref","first-page":"115432","DOI":"10.1016\/j.ejca.2025.115432","article-title":"Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers","volume":"222","author":"Smolenschi","year":"2025","journal-title":"Eur J Cancer"},{"key":"R56-20261029","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1158\/1078-0432.CCR-25-4464","article-title":"Shaping the future of HER2-directed therapy in biliary tract cancer","volume":"32","author":"Fitzpatrick","year":"2026","journal-title":"Clin Cancer Res"},{"key":"R57-20261029","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2020.08.006","article-title":"Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer","volume":"105","author":"Hiraoka","year":"2020","journal-title":"Hum Pathol"},{"key":"R58-20261029","doi-asserted-by":"crossref","first-page":"652","DOI":"10.21037\/jgo.2018.08.18","article-title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","volume":"10","author":"Weinberg","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"R59-20261029","doi-asserted-by":"crossref","first-page":"eaay0152","DOI":"10.1126\/scitranslmed.aay0152","article-title":"PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma","volume":"12","author":"Jiang","year":"2020","journal-title":"Sci Transl Med"},{"key":"R60-20261029","doi-asserted-by":"crossref","first-page":"eadd7464","DOI":"10.1126\/scitranslmed.add7464","article-title":"PTEN deficiency facilitates gemcitabine efficacy in cancer by modulating the phosphorylation of PP2Ac and DCK","volume":"15","author":"Jiang","year":"2023","journal-title":"Sci Transl Med"},{"key":"R61-20261029","doi-asserted-by":"crossref","first-page":"105540","DOI":"10.1016\/j.esmoop.2025.105540","article-title":"Molecular profile and clinical impact of MDM2 amplification in patients with advanced biliary tract cancer","volume":"10","author":"Yoon","year":"2025","journal-title":"ESMO Open"},{"key":"R62-20261029","doi-asserted-by":"crossref","first-page":"105049","DOI":"10.1016\/j.esmoop.2025.105049","article-title":"Claudin 18.2: A promising actionable target in biliary tract cancers","volume":"10","author":"Angerilli","year":"2025","journal-title":"ESMO Open"},{"key":"R63-20261029","doi-asserted-by":"crossref","first-page":"eadj7685","DOI":"10.1126\/scitranslmed.adj7685","article-title":"SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma","volume":"16","author":"Luk","year":"2024","journal-title":"Sci Transl Med"},{"key":"R64-20261029","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12943-024-02190-w","article-title":"Persistent response to combination therapy of pemigatinib and chemotherapy in a child of combined hepatocellular-cholangiocarcinoma with FGFR2 fusion","volume":"23","author":"He","year":"2024","journal-title":"Mol Cancer"},{"key":"R65-20261029","doi-asserted-by":"crossref","first-page":"15","DOI":"10.17305\/bjbms.2022.7953","article-title":"PD-L1 testing by immunohistochemistry in immuno-oncology","volume":"23","author":"Vranic","year":"2023","journal-title":"Biomol Biomed"},{"key":"R66-20261029","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.18632\/oncotarget.26998","article-title":"Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma","volume":"10","author":"Ang","year":"2019","journal-title":"Oncotarget"},{"key":"R67-20261029","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"key":"R68-20261029","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/modpathol.2016.122","article-title":"Correlation of exon 3 \u03b2-catenin mutations with glutamine synthetase staining patterns in hepatocellular adenoma and hepatocellular carcinoma","volume":"29","author":"Hale","year":"2016","journal-title":"Mod Pathol"},{"key":"R69-20261029","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma","volume":"9","author":"Ruiz de Galarreta","year":"2019","journal-title":"Cancer Discov"},{"key":"R70-20261029","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.7150\/jca.71494","article-title":"Effect of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma harboring CTNNB1 mutation in early clinical experience","volume":"13","author":"Ogawa","year":"2022","journal-title":"J Cancer"},{"key":"R71-20261029","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3892\/ol.2022.13337","article-title":"Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT\/\u03b2-catenin signal activation","volume":"24","author":"Kuwano","year":"2022","journal-title":"Oncol Lett"},{"key":"R72-20261029","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3350\/cmh.2025.0792","article-title":"Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features","volume":"32","author":"Lee","year":"2026","journal-title":"Clin Mol Hepatol"},{"key":"R73-20261029","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41392-025-02520-4","article-title":"Dysadherin\/YAP axis fuels stem plasticity and immune escape in liver cancer","volume":"10","author":"Jang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R74-20261029","doi-asserted-by":"crossref","first-page":"10039","DOI":"10.1038\/s41467-025-65945-z","article-title":"Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation","volume":"16","author":"Wu","year":"2025","journal-title":"Nat Commun"},{"key":"R75-20261029","doi-asserted-by":"crossref","first-page":"e011537","DOI":"10.1136\/jitc-2025-011537","article-title":"Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma","volume":"13","author":"Dadey","year":"2025","journal-title":"J Immunother Cancer"},{"key":"R76-20261029","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"R77-20261029","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/cac2.12607","article-title":"Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma","volume":"44","author":"Cai","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"R78-20261029","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jhep.2024.02.009","article-title":"CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma","volume":"81","author":"Xie","year":"2024","journal-title":"J Hepatol"},{"key":"R79-20261029","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.7150\/thno.99046","article-title":"DAB2 (+) macrophages support FAP (+) fibroblasts in shaping tumor barrier and inducing poor clinical outcomes in liver cancer","volume":"14","author":"Long","year":"2024","journal-title":"Theranostics"},{"key":"R80-20261029","first-page":"620-634","article-title":"Galectin-4 drives anti-PD-L1\/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma","volume":"75(3)","author":"Xu","year":"2025","journal-title":"Gut"},{"key":"R81-20261029","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1136\/gutjnl-2023-331342","article-title":"Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8(+) T cell-mediated antitumour immunity and improves anti-PD-1 efficacy","volume":"73","author":"Cai","year":"2024","journal-title":"Gut"},{"key":"R82-20261029","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1053\/j.gastro.2020.03.074","article-title":"Hepatocellular carcinoma cells up-regulate PVRL1, stabilizing PVR and inhibiting the cytotoxic T-cell response via TIGIT to mediate tumor resistance to PD1 inhibitors in mice","volume":"159","author":"Chiu","year":"2020","journal-title":"Gastroenterology"},{"key":"R83-20261029","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/HEP.0000000000001433","article-title":"Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy","volume":"83","author":"Su","year":"2026","journal-title":"Hepatology"},{"key":"R84-20261029","doi-asserted-by":"crossref","first-page":"e0925","DOI":"10.1097\/HC9.0000000000000925","article-title":"Construction of TLS-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma","volume":"10","author":"Li","year":"2026","journal-title":"Hepatol Commun"},{"key":"R85-20261029","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.2147\/JHC.S568933","article-title":"A grading system of intratumoral tertiary lymphoid structure for combined hepatocellular-cholangiocarcinoma: A multicenter pathological study","volume":"12","author":"Wang","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"key":"R86-20261029","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"R87-20261029","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"R88-20261029","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-24-0517","article-title":"FDA approval summary: Durvalumab and pembrolizumab, immune checkpoint inhibitors for the treatment of biliary tract cancer","volume":"30","author":"Casak","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R89-20261029","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: Updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"key":"R90-20261029","doi-asserted-by":"crossref","first-page":"116032","DOI":"10.1016\/j.ejca.2025.116032","article-title":"Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient biliary tract cancer: An AGEO study","volume":"230","author":"Huang","year":"2025","journal-title":"Eur J Cancer"},{"key":"R91-20261029","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3892\/ol.2021.13122","article-title":"Low prevalence of biliary tract cancer with defective mismatch repair genes in a Japanese hospital-based population","volume":"23","author":"Ando","year":"2022","journal-title":"Oncol Lett"},{"key":"R92-20261029","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3892\/ol.2016.5477","article-title":"Imbalanced adaptive responses associated with microsatellite instability in cholangiocarcinoma","volume":"13","author":"Loilome","year":"2017","journal-title":"Oncol Lett"},{"key":"R93-20261029","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1200\/JCO.24.00337","article-title":"Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: Clinical and biomarker data from the randomized phase II IMbrave151 trial","volume":"43","author":"Macarulla","year":"2025","journal-title":"J Clin Oncol"},{"key":"R94-20261029","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41392-025-02356-y","article-title":"First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): A multicenter, single-arm, phase 2 study","volume":"10","author":"Shi","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R95-20261029","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jhep.2025.10.032","article-title":"Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer","volume":"84","author":"Yoon","year":"2026","journal-title":"J Hepatol"},{"key":"R96-20261029","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/HEP.0000000000001138","article-title":"The co-location of MARCO+ tumor-associated macrophages and CTSE+ tumor cells determined the poor prognosis in intrahepatic cholangiocarcinoma","volume":"82","author":"Fan","year":"2025","journal-title":"Hepatology"},{"key":"R97-20261029","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jhep.2025.03.035","article-title":"Tumor-derived CD109 orchestrates reprogramming of tumor-associated macrophages to dampen immune response","volume":"83","author":"Cui","year":"2025","journal-title":"J Hepatol"},{"key":"R98-20261029","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ccell.2025.05.017","article-title":"Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma","volume":"43","author":"Huang","year":"2025","journal-title":"Cancer Cell"},{"key":"R99-20261029","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1158\/2159-8290.CD-25-1844","article-title":"Arachidonic acid metabolism in PMN-MDSCs suppresses antitumor capacity of T cells in KRAS-mutant cholangiocarcinoma","volume":"16","author":"Lin","year":"2026","journal-title":"Cancer Discov"},{"key":"R100-20261029","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jhep.2025.09.018","article-title":"PARG inhibition halts cholangiocarcinoma progression via the Hippo pathway and enhances response to chemotherapy and immunotherapy","volume":"84","author":"Yu","year":"2026","journal-title":"J Hepatol"},{"key":"R101-20261029","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1038\/s41467-022-33746-3","article-title":"The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma","volume":"13","author":"Bauer","year":"2022","journal-title":"Nat Commun"},{"key":"R102-20261029","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1038\/s41591-025-03995-y","article-title":"A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: A phase 1 trial","volume":"31","author":"Baretti","year":"2025","journal-title":"Nat Med"},{"key":"R103-20261029","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/gutjnl-2025-335456","article-title":"Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial","volume":"75","author":"Wu","year":"2025","journal-title":"Gut"},{"key":"R104-20261029","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: A phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat Med"},{"key":"R105-20261029","doi-asserted-by":"crossref","first-page":"11111","DOI":"10.1038\/s41467-025-66087-y","article-title":"Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma","volume":"16","author":"Huang","year":"2025","journal-title":"Nat Commun"},{"key":"R106-20261029","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12943-025-02538-w","article-title":"Synergistic innate-adaptive immunity by NKG2D-specific CAR-macrophages drives durable remission in hepatocellular carcinoma","volume":"25","author":"Zhao","year":"2025","journal-title":"Mol Cancer"},{"key":"R107-20261029","doi-asserted-by":"crossref","first-page":"551","DOI":"10.14218\/JCTH.2023.00559","article-title":"A blood hepatocellular carcinoma signature recognizes very small tumor nodules with metastatic traits","volume":"12","author":"Chen","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"R108-20261029","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/clinchem\/hvad168","article-title":"Circulating tumor DNA clinical applications in hepatocellular carcinoma: Current trends and future perspectives","volume":"70","author":"Bardol","year":"2024","journal-title":"Clin Chem"},{"key":"R109-20261029","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/hep.31230","article-title":"Cell-free virus-host chimera DNA from hepatitis B virus integration sites as a circulating biomarker of hepatocellular cancer","volume":"72","author":"Li","year":"2020","journal-title":"Hepatology"},{"key":"R110-20261029","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jcmgh.2023.01.001","article-title":"Hepatitis B virus DNA integration drives carcinogenesis and provides a new biomarker for HBV-related HCC","volume":"15","author":"Yeh","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"R111-20261029","doi-asserted-by":"crossref","first-page":"1235260","DOI":"10.3389\/fgene.2023.1235260","article-title":"Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma","volume":"14","author":"Kumar","year":"2023","journal-title":"Front Genet"},{"key":"R112-20261029","doi-asserted-by":"crossref","first-page":"218212","DOI":"10.1016\/j.canlet.2025.218212","article-title":"Application of targeted deep sequencing for management of hepatocellular carcinoma in a real-world setting: prediction of MRD and adjuvant lenvatinib response","volume":"639","author":"Zhang","year":"2026","journal-title":"Cancer Lett"},{"key":"R113-20261029","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1186\/s12885-021-08204-w","article-title":"Dynamic change of serum CA19-9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas","volume":"21","author":"Zhao","year":"2021","journal-title":"BMC Cancer"},{"key":"R114-20261029","doi-asserted-by":"crossref","first-page":"405","DOI":"10.14309\/ajg.0000000000002190","article-title":"ACG Clinical Guideline: Diagnosis and management of biliary strictures","volume":"118","author":"Elmunzer","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"R115-20261029","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41392-024-01814-3","article-title":"Cholangiocarcinoma combined with biliary obstruction: An exosomal circRNA signature for diagnosis and early recurrence monitoring","volume":"9","author":"Wen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R116-20261029","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1136\/gutjnl-2024-331956","article-title":"Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments","volume":"73","author":"Campani","year":"2024","journal-title":"Gut"},{"key":"R117-20261029","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/cancers17061042","article-title":"The current role of circulating cell-free DNA in the management of hepatocellular carcinoma","volume":"17","author":"Papatheodoridi","year":"2025","journal-title":"Cancers (Basel)"},{"key":"R118-20261029","doi-asserted-by":"crossref","first-page":"e013381","DOI":"10.1136\/jitc-2025-013381","article-title":"PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with hepatocellular carcinoma receiving PD-(L)1 blockade and targeted therapy","volume":"14","author":"Gong","year":"2026","journal-title":"J Immunother Cancer"},{"key":"R119-20261029","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-23-3780","article-title":"Clinical value of liquid biopsy in patients with FGFR2 fusion-positive cholangiocarcinoma during targeted therapy","volume":"30","author":"Gonz\u00e1lez-Medina","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R120-20261029","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2024.11.017","article-title":"Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann Oncol"},{"key":"R121-20261029","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/PO.20.00178","article-title":"Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations","volume":"5","author":"Varghese","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"R122-20261029","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"key":"R123-20261029","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jhep.2023.10.041","article-title":"Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma","volume":"80","author":"DiPeri","year":"2024","journal-title":"J Hepatol"},{"key":"R124-20261029","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.annonc.2026.01.004","article-title":"Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib","volume":"37","author":"Ellis","year":"2026","journal-title":"Ann Oncol"},{"key":"R125-20261029","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1158\/1078-0432.CCR-25-4390","article-title":"Recurrent resistance mutations to lirafugratinib inform treatment sequencing in FGFR2-driven tumors","volume":"32","author":"Facchinetti","year":"2026","journal-title":"Clin Cancer Res"},{"key":"R126-20261029","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/1078-0432.CCR-25-3284","article-title":"MAPK pathway mutations emerge in mutant IDH1 inhibitor-resistant cholangiocarcinoma and attenuate the IFN response","volume":"32","author":"Wan","year":"2026","journal-title":"Clin Cancer Res"},{"key":"R127-20261029","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41392-026-02649-w","article-title":"Activation of nerve growth factor signaling limits the response to lenvatinib in hepatocellular carcinoma","volume":"11","author":"Xu","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"R128-20261029","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3350\/cmh.2025.0972","article-title":"ERBB3 blockade sensitizes hepatocellular carcinoma to regorafenib after first-line tyrosine kinase inhibitor resistance by inhibiting HIF1A-ABCB1 signaling","volume":"32","author":"Tao","year":"2026","journal-title":"Clin Mol Hepatol"},{"key":"R129-20261029","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.apsb.2025.12.007","article-title":"Deuterium modification of tyrosine kinase inhibitors contributes to reversing ferroptosis resistance through upregulation of aldehyde oxidase 1 in hepatocellular carcinoma","volume":"16","author":"Ma","year":"2026","journal-title":"Acta Pharm Sin B"},{"key":"R130-20261029","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1136\/gutjnl-2018-317440","article-title":"Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance","volume":"68","author":"Xiang","year":"2019","journal-title":"Gut"},{"key":"R131-20261029","doi-asserted-by":"crossref","first-page":"6699","DOI":"10.1038\/s41467-023-42360-w","article-title":"Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma","volume":"14","author":"Leung","year":"2023","journal-title":"Nat Commun"},{"key":"R132-20261029","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1053\/j.gastro.2026.02.040","article-title":"DNA\/RNA-based next-generation sequencing improves the early diagnosis and management of neoplastic bile duct strictures: A 6-year, prospective, multi-institutional, real-time study","volume":"171","author":"Das","year":"2026","journal-title":"Gastroenterology"},{"key":"R133-20261029","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/gutjnl-2018-317817","article-title":"Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures","volume":"69","author":"Singhi","year":"2020","journal-title":"Gut"},{"key":"R134-20261029","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccell.2024.03.004","article-title":"Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer","volume":"42","author":"Yang","year":"2024","journal-title":"Cancer Cell"},{"key":"R135-20261029","doi-asserted-by":"crossref","first-page":"e222729","DOI":"10.1148\/radiol.222729","article-title":"Predicting microvascular invasion in hepatocellular carcinoma using CT-based radiomics model","volume":"307","author":"Xia","year":"2023","journal-title":"Radiology"},{"key":"R136-20261029","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.dld.2024.06.033","article-title":"CT-based radiogenomics of intrahepatic cholangiocarcinoma","volume":"57","author":"Vigan\u00f2","year":"2025","journal-title":"Dig Liver Dis"},{"key":"R137-20261029","doi-asserted-by":"crossref","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: Updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"R138-20261029","doi-asserted-by":"crossref","first-page":"e082505","DOI":"10.1136\/bmj-2024-082505","article-title":"PROBAST+AI: An updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"BMJ"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/HC9.0000000000001069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:00:41Z","timestamp":1793271641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/HC9.0000000000001069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":138,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/hc9.0000000000001069","relation":{},"ISSN":["2471-254X"],"issn-type":[{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"2026-05-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}